How to Use Precedent Transaction Analysis to Value Companies

Precedent transaction analysis estimates a company's value by examining the prices paid for similar companies in recent acquisitions. This model is particularly useful for assessing the potential value in merger and acquisition (M&A) scenarios, as it reflects actual market prices paid for comparable businesses.

This article will explain the precedent transaction analysis method, compare it to the comparable company analysis (comps), and guide investors on identifying precedent transactions. It will also discuss how to find recent M&A transaction data and gather relevant information. A real-world example and a free Excel template will be provided to illustrate the application of this valuation model. Lastly, the article will discuss the model's advantages and limitations.

Precedent Transaction Analysis Explained

Precedent transaction analysis, also known as "M&A comps" or "transaction comps," is a relative valuation methodology that estimates a company's worth by examining the prices paid for similar companies in recent acquisitions. This approach helps determine a fair price range for a potential acquisition target by considering the historical transaction values of comparable businesses.

The premise behind precedent transaction analysis is that the prices paid in previous comparable transactions indicate the market's valuation of a company at that time. By studying the transaction details, such as the purchase price, implied valuation multiples, and any premiums paid above the market price, investors can gain insights into the valuation levels that acquirers are willing to pay for companies with similar characteristics.

However, precedent transaction analysis can be challenging for retail investors to apply effectively. This is because access to detailed information on private transactions is often limited, and the data available through public sources may be incomplete or outdated. Additionally, the analysis requires a deep understanding of the target company's industry, the specific transaction dynamics, and the broader market conditions at the time of each transaction.

Due to these limitations, precedent transaction analysis is often considered optional or, at most, supplemental to other valuation methods. Nevertheless, this valuation approach is grounded in reality, being based on actual prices paid by acquirers for similar companies. Therefore, unlike other valuation models that rely heavily on assumptions and projections, precedent transaction analysis provides a more concrete basis for assessing a company's potential value in an M&A context.

Precedent Transaction Analysis vs. Comparable Company Analysis

Precedent transaction analysis and comparable company analysis (aka "comps" or "trading comps") are both relative valuation methods used to estimate the value of a company. Although the model formats are similar, there are notable differences between the two approaches.

Related: How to Perform Relative Valuation Using Comparable Company Analysis

The table below provides a detailed comparison of precedent transaction analysis and comparable company analysis:

In short, comps focus on the current trading multiples of publicly listed companies that are similar to the target company, assuming that the market efficiently prices these comparable companies. It uses current market data and reflects present market conditions and industry trends affecting the company's valuation.

In contrast, precedent transaction analysis examines the actual prices paid in historical M&A transactions involving companies similar to the target, considering the "control premium" that acquirers are willing to pay. This approach relies on historical data and may not fully reflect current market conditions or industry trends.

A control premium is the additional amount an acquirer pays above the target company's pre-acquisition market price to gain a controlling stake in the company. This premium reflects the acquirer's perceived benefits of having control, such as the ability to realize synergies (i.e., the expected financial benefits from combining two businesses) or implement strategic changes.

Notably, the existence of a control premium and various synergies in precedent transactions typically leads to higher valuation multiples compared to those derived from comps.

How to Identify Relevant Precedent Transactions

The first step in any precedent transaction analysis is to identify appropriate precedent transactions. The relevance and comparability of these transactions directly impact the accuracy and usefulness of the entire valuation.

In precedent transaction analysis, the focus is on the characteristics of the seller (target company) rather than the buyer. This is because the goal is to value the company being analyzed based on the prices paid for similar companies, making the seller's profile more relevant for determining comparability.

Selecting the right precedent transactions involves some subjectivity and may require adjustments based on the specific characteristics of the company being valued. It's important for investors to consider each criterion and make informed judgments to ensure that the most relevant and comparable transactions are included in the analysis.

The following lists highlight the key business and financial profiles investors should identify when selecting comparable precedent transactions, sharing the same profiles as a trading comps analysis:

When evaluating these profiles, it's especially important in precedent transaction analysis to consider the timing of transactions and other transaction-specific characteristics.

Recent transactions, such as those within the trailing twelve months (TTM), are generally preferable as they better reflect current market conditions and industry trends. However, the appropriate time frame depends on the availability of relevant deals. If there are insufficient comparable transactions within the TTM period, expanding the time frame to include older deals may be necessary. However, the older the transaction, the less relevant it is to the current market state and valuation.

Lastly, transaction-specific characteristics, such as whether the buyer was a strategic or financial acquirer, whether it was a full auction or a negotiated deal, and the purchase consideration (cash, stock, or a combination of both), are important to understand. These factors provide deeper insights into the transaction dynamics. These precedent transaction analysis synergy considerations are discussed in the following section.

Synergies in Precedent Transaction Analysis

Once an initial set of comparable acquisitions has been selected, it's important to understand the specific circumstances and context of each transaction, as these factors can affect their weighting in the precedent transaction analysis. One key factor to consider is synergies, which refer to the expected cost savings, revenue enhancements, and other financial benefits that result from combining two businesses.

Synergies provide tangible value to the acquirer through future cash flows and earnings that are greater than what the target company (the company being acquired) could generate on its own. The size and likelihood of these synergies significantly influence the acquirer’s willingness to pay a higher (or lower) purchase price for the target.

The various synergies that can influence the valuation multiples and premiums paid in a precedent transaction analysis are discussed below.

Strategic vs. Financial Buyers

Understanding the differences between strategic and financial buyers is key in a precedent transaction analysis, as the type of buyer can significantly impact the valuation multiples and synergies realized in a transaction:

• Strategic Buyers: Operating companies within the same or related industries that seek to realize synergies or expand market share. These buyers are often competitors, suppliers, or customers of the target firm. They may also be unrelated to the target's industry but recognize the potential for synergies.
• Financial Buyers: Investment firms or high net worth individuals, including private equity, venture capital, hedge funds, and family investment offices. These buyers focus on generating returns through financial engineering and operational improvements. They invest in companies with the goal of realizing a return on their investments.

The key differences between strategic and financial buyers, and their significance regarding synergies within precedent transaction analysis, are discussed in the table below:

In short, strategic buyers generally have a greater potential to realize synergies in precedent transactions due to their industry expertise, ability to integrate the target company, and long-term investment horizon. This potential for synergies can lead to higher valuation multiples compared to financial buyers, who typically focus on standalone value creation and short to medium-term returns.

Motivations Behind the Transaction

There are countless motivations behind a sale, and it's important for investors to seek out why the company pursued such a transaction. Understanding the rationale behind the deal can provide valuable insights into the valuation multiples and premiums paid.

Note that it's important to consider the motivations of both the buyer and the seller, as each party's objectives can significantly influence the transaction dynamics and outcomes.

Some questions that may need to be addressed include:

• Is the seller looking to divest a non-core asset?
• Is the buyer seeking to acquire a strategic asset or expand into new markets?
• Is the target company in financial distress, necessitating a quick sale?
• Is the transaction a result of a fire sale, where assets are disposed of quickly, often at a discounted price?
• Are there any regulatory or competitive pressures driving the transaction?

For example, in 2021, AT&T announced plans to spin off its WarnerMedia division and merge it with Discovery to create a new standalone media company. This transaction was driven by AT&T's desire to refocus on its core telecommunications business and reduce its debt load. This motivation would suggest that the valuation multiples for the WarnerMedia transaction might not be directly comparable to other media deals where the seller may not be under pressure to divest a non-core asset.

Sale Process and Nature of the Deal

The sale process and nature of the deal are important factors to consider in precedent transaction analysis, as they can significantly impact the valuation multiples and premiums paid. Understanding how the transaction was structured and executed can provide valuable insights into the competitive dynamics and motivations behind the deal.

Key terms and concepts related to the sale process and nature of the deal include:

• Auction Process: Sale process in which the target company is marketed to multiple potential buyers, creating competitive dynamics that can drive up the purchase price and valuation multiples.
• Negotiated Deal: Transaction involving a limited number of parties, often resulting in lower valuation multiples compared to auction processes.
• Hostile Takeover: Situation in which the target company actively seeks alternatives to a proposed acquisition, potentially leading to higher purchase prices as the target attempts to fend off the acquirer.
• Merger of Equals (MOE): A transaction in which two companies combine to form a larger entity, typically focusing on preserving cash for the future of the combined company rather than generating high valuation multiples.

In summary, auction processes and hostile takeovers tend to drive up valuations, while negotiated deals and mergers of equals may result in lower multiples.

Purchase Consideration

The form of consideration used in a precedent transaction, such as cash, stock, or a combination, can significantly impact the valuation multiples and premiums paid. Understanding how different types of purchase consideration affect a deal is essential when analyzing and comparing transactions.

The three main types of purchase consideration are described below:

• All-Cash Transactions: The acquirer pays for the target company entirely in cash. All-cash transactions generally result in higher valuation multiples and premiums compared to deals involving stock consideration. This is because target shareholders receive immediate and certain value for their shares and do not retain any ongoing interest in the combined company.
• Stock-for-Stock Transactions: The acquirer pays for the target company using its own shares. When a significant portion of the consideration is in stock, it tends to result in lower valuation multiples and premiums compared to all-cash transactions. This is because target shareholders retain an equity interest in the combined entity and can participate in future growth and synergies. Moreover, they maintain the opportunity to obtain a control premium through a future sale of the company.
• Cash and Stock Transactions: A combination of cash and stock is used as consideration. The impact on valuation multiples and premiums will depend on the relative proportions of cash and stock in the deal.

In summary, all-cash deals often result in higher valuations, while transactions involving stock consideration may lead to lower multiples, as target shareholders retain an interest in the combined company.

It's important to note that the form of purchase consideration also affects how equity value is calculated in a precedent transaction analysis. In an all-cash deal, the equity value is simply the cash offer price per share multiplied by the number of fully diluted shares outstanding.

However, when stock is used, the equity value must account for the value of the acquirer's shares issued to target shareholders. This calculation is based on either a "fixed exchange ratio" or a "floating exchange ratio" and follows a more involved process, as discussed in the example further below in this article.

Domestic vs. Cross-Border Transactions

Precedent transactions involving parties from the same country (domestic) may be subject to different dynamics compared to those involving parties from different countries (cross-border).

Cross-border deals can be more complex due to differences in regulatory environments, tax implications, and cultural considerations. For example, varying legal frameworks can lead to additional compliance costs, differing tax structures can affect the net proceeds of the transaction, and cultural differences can impact integration processes.

These factors can result in higher or lower valuation multiples and premiums paid in cross-border transactions compared to domestic ones.

How to Find Relevant Precedent Transactions Information

Finding relevant information on precedent transactions is a necessary step in conducting a thorough and accurate analysis. While there are several sources available, the accessibility and depth of information can vary depending on the nature of the transaction and the parties involved. This section will discuss the various avenues for locating precedent transaction data and explain the key terms and filings involved.

Note that if you cannot find relevant deals or sufficient information, conducting a precedent transaction analysis may not be worthwhile. Investors should aim to include at least 5-10 deals in their analysis, or as many relevant deals as possible. Quality should take precedence over quantity, but there should be enough transactions to make the valuation meaningful.

Here’s a table that provides an overview of the transaction-specific information items for public and private companies and where they can be sourced:

Source: Investment Banking: Valuation, Leveraged Buyouts, and Mergers & Acquisitions, Second Edition

As you can see, several key sources of information are available for precedent transaction analysis. When gathering transaction data, prioritize primary sources, such as company filings and press releases, over secondary sources like databases, which may require additional verification. Equity research and M&A reports can also be reliable if cross-checked against company disclosures. The following sections define and explain these sources in greater detail.

Databases

Financial databases serve as one of the primary sources for precedent transaction information. These platforms provide extensive data on M&A transactions and enable users to search and filter deals based on particular criteria:

• Securities Data Corporation (SDC): SDC is a leading provider of M&A data, offering a searchable database of completed transactions. Investors can conduct an "SDC run" to identify transactions that meet specific criteria, such as industry, time frame, deal size, and geography. Access to SDC requires a paid subscription, although free access may be available through university or institutional subscriptions. Investors should verify data obtained from SDC through other sources, as the results may not be comprehensive.
• Capital IQ, FactSet, and PrivCo: These financial databases offer advanced search features for M&A transactions, allowing users to filter deals based on financial, geographic, industry, and date criteria. While these platforms are generally the best options for quickly sourcing precedent transactions and are used by professional investors and institutions, they may be largely inaccessible to the average retail investor due to high subscription costs.

In summary, while databases offer comprehensive data and powerful search capabilities, they may be inaccessible to individual investors due to pricing.

SEC Filings

Securities and Exchange Commission (SEC) filings are valuable sources of precedent transaction information. Public companies must disclose material information related to M&A transactions through various filings, providing a wealth of data for investors. The following SEC filings can provide valuable information on precedent transactions:

• Merger Proxies/Proxy Statements (Schedule 14A): These documents provide shareholders with information about proposed merger transactions for voting at a shareholder meeting. They are required for obtaining shareholder approval for significant corporate actions, including mergers. Additionally, if the acquirer issues more than 20% of its pre-deal outstanding shares as consideration for the merger, a proxy statement is necessary. These documents include a summary of transaction terms, a description of the financial analysis by the target's financial advisors, and their fairness opinions. The "opinion of financial advisor" section often lists comparable transactions used in the valuation analysis and may contain a "fairness opinion," assessing the financial fairness of the transaction terms.
• Tender Offer Documents (Schedule TO and Schedule 14D-9): In a tender offer, the acquirer offers to buy shares directly from the target's shareholders. Schedule TO, submitted by the acquirer, includes the terms of the tender offer and other relevant information. In response, the target company files Schedule 14D-9 within 10 business days, containing the board's recommendation to shareholders on whether to accept or reject the offer, along with a fairness opinion. These filings provide valuable information on the transaction, including the offer price, the number of shares sought, and any conditions attached to the offer.
• 8-K Filings: Form 8-K is filed by public companies to announce major events, such as significant acquisitions or divestitures. Key deal information, including the transaction price, terms, and a brief description of the acquired assets, can often be found in the 8-K filed upon the announcement of the transaction. Public targets must file an 8-K within 4 business days of the transaction announcement, and parent companies selling a significant subsidiary or division will also typically file an 8-K.
• 10-K Annual Reports and 10-Q Quarterly Reports: These periodic reports disclose financial performance and other relevant information. The 10-K is an annual report providing a comprehensive overview of the company's business and financial condition, while the 10-Q is a quarterly report including unaudited financial statements and a discussion of the company's performance. These reports may discuss recent transactions in the context of the competitive landscape and can be used to calculate the target's TTM (trailing twelve months) financial data as of the most recent period ended before the transaction announcement date.
• Registration Statement/Prospectus (S-4, 424B): A registration statement is filed with the SEC by a company wanting to offer securities to the public. When a public acquirer issues shares as consideration in a merger or acquisition, it must file a registration statement on Form S-4 (for a stock swap) or a prospectus supplement on Form 424B (for a cash and stock deal). These filings include detailed information about the transaction terms, the financial statements of both companies, and the risks associated with the combined entity.
• Schedule 13E-3: Schedule 13E-3 is a filing required by the SEC when a public company is taken private by an affiliate of the company, such as a senior executive or significant shareholder. This filing provides detailed information about the terms of the transaction, the parties involved, and the fairness of the deal to unaffiliated shareholders. Schedule 13E-3 is typically filed in connection with a management buyout or a leveraged buyout of a public company.

In summary, SEC filings, such as merger proxies, tender offer documents, and periodic reports, provide detailed information about specific transactions but may require more effort to locate and analyze than simply searching through a database.

Company Reports, Industry Publications, and Previous Valuation Analyses

In addition to SEC filings, investors can find valuable information on precedent transactions in company reports and industry publications. The following sources can provide useful insights and data:

• Equity Research Reports and Industry Publications: Equity research reports prepared by securities analysts covering the target company's industry sometimes provide detailed analysis and commentary on significant transactions. These reports may include information on deal multiples, transaction rationale, and the potential impact on the industry. Industry-specific trade publications can also be valuable sources of information on M&A activity and trends. To find these reports, investors can search for the target company's name, ticker symbol, or industry keywords along with terms like "equity research report," "analyst report," or "industry report" on search engines or financial news websites.
• M&A Industry Reports: Leading accounting firms, such as the Big 4 (Deloitte, PwC, EY, and KPMG), and boutique investment banks often publish periodic reports on M&A activity in specific industries. These reports typically include data on deal volume, average transaction multiples, and notable transactions. To find these reports, investors can search for the industry name along with keywords like "M&A report," "mergers and acquisitions," or "transaction multiples" on the websites of the accounting firms or investment banks, or through search engines.
• Previous Valuation Analyses: Presentation materials, such as pitch books or fairness opinion presentations from previous transactions in the same industry, can be valuable sources of precedent transaction data. These materials often include detailed information on the target company, the transaction terms, and the valuation analysis performed by the financial advisors. While these documents may not be publicly available, investors can sometimes find them by searching for the target company's name or the transaction description along with keywords like "fairness opinion presentation," "valuation analysis," or "investment banking presentation" on search engines or industry-specific websites.

In summary, while company reports, industry publications, M&A reports, and previous valuation analyses may not be as readily available or comprehensive as databases or SEC filings, they can still provide valuable insights for precedent transaction analyses.

Important Transaction-Specific Information for Precedent Transactions Analysis

Once the relevant precedent transactions have been identified, investors need to gather and analyze key information to build out the precedent transaction analysis model. This process involves collecting data on the target company, acquirer, deal terms, and financial metrics for each transaction. The level of detail available may vary depending on whether the target company was publicly traded or private.

Must-Have Information for Building the Analysis

• Announcement Date: The announcement date is crucial for identifying the market conditions and economic environment at the time of the transaction. This information helps ensure that the financial metrics and multiples used in the analysis are relevant and comparable.
• Target Company Details: Gather information about the target company, including its business description, industry, and key products or services. This information is essential for determining the comparability of the target company to the company being valued.
• Transaction Value: Record the total value of the transaction, including the equity value (price paid for the target company's equity) and the enterprise value (which includes any assumed debt and other considerations). Both the equity value and enterprise value are typically used as the basis for calculating valuation multiples.
• Consideration and Deal Terms: Note the form of consideration (cash, stock, or a combination) and any contingent payments or earn-outs, as these factors can affect the implied valuation. Understanding the purchase price and other key deal terms is essential for accurately interpreting the transaction value.
• Target Company Financial Metrics: To calculate valuation multiples, gather the target company's revenue, EBITDA (earnings before interest, taxes, depreciation, and amortization), EBIT (earnings before interest and taxes), and net income for the most recent twelve months (TTM) prior to the transaction announcement. These metrics will be used as the denominators in the valuation multiples.

Nice-to-Have Information for Improving the Analysis

• Acquirer Company Details: Collect information about the acquirer, including its business model, financial strength, and acquisition strategy. This information can provide insights into the transaction rationale and the potential synergies driving the deal value.
• Control Premium: For transactions involving public targets, calculate the premium paid by the acquirer over the target company's pre-announcement share price (e.g., 1 day, 1 week, or 1 month prior to the announcement). The control premium reflects the value of gaining control of the company and can provide insights into the level of synergies or strategic value perceived by the acquirer.
• Strategic Rationale: Identify the primary motivations behind each transaction, such as expanding market share, acquiring new technologies or capabilities, or realizing cost synergies. Understanding the strategic rationale can help assess the comparability of the transaction to the current valuation context.
• Market Reaction: For transactions involving publicly traded acquirers, analyze the stock price reaction following the transaction announcement. This can provide insights into the market's perception of the deal and its potential impact on the combined entity's value.
• Deal Terms and Conditions: Review the key terms and conditions of each transaction, including any regulatory approvals, financing contingencies, or termination fees. These factors can impact the certainty and timing of the transaction closing and may affect the valuation.

By gathering this information for each precedent transaction, investors can build a comprehensive model that enables them to calculate relevant valuation multiples, assess the comparability of the transactions to the company being valued, and derive meaningful insights into the appropriate valuation range. While the must-have information is necessary for conducting the analysis, the nice-to-have information can enhance the depth and accuracy of the valuation conclusions.

It's important to note that the availability and reliability of this information may vary depending on the specific transaction and the sources used. Publicly traded companies generally disclose more detailed information than private companies, and the level of granularity in the disclosure may differ across jurisdictions. Nonetheless, by diligently searching for and compiling the most relevant and reliable data, investors can build a precedent transaction analysis that provides valuable insights into the potential value of the company being evaluated.

Precedent Transaction Analysis Example

To demonstrate how to value stocks using precedent transaction analysis, we'll use Mersana Therapeutics (MRSN) as our example company. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for various cancers.

Mersana Therapeutics, as a biopharmaceutical company developing novel cancer therapies, is a suitable company for precedent transaction analysis due to the high level of M&A activity in the oncology space. Many large pharmaceutical companies are actively seeking to acquire promising cancer treatment assets to bolster their pipelines and maintain a competitive edge in the market.

Here's the five steps investors can follow to estimate the value of Mersana Therapeutics using precedent transaction analysis, as explained in greater detail in the following sections:

• Step #1: Select the Universe of Comparable Acquisitions
• Step #2: Locate the Necessary Deal-Related and Financial Information
• Step #3: Spread Key Statistics, Ratios, and Transaction Multiples
• Step #4: Benchmark the Comparable Acquisitions
• Step #5: Imply Valuation

Step #1: Select the Universe of Comparable Acquisitions

Selecting the appropriate universe of comparable acquisitions is the most important step in precedent transaction analysis, as it lays the foundation for the valuation process. However, it's also the most challenging step, particularly compared to trading comps.

The universe of comparable public companies is generally larger than the pool of relevant M&A transactions, and the data for public companies is more accessible and standardized. In contrast, finding complete data on M&A transactions is difficult, with information often inconsistent or incomplete.

For our example, given that Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for various cancers, we searched for transactions involving target companies with similar business models and therapeutic focus areas.

Using PitchBook's database (which is paid but speeds up the process), we identified ten potentially suitable precedent transactions in the oncology space. Below is a table breaking down the acquirer name, target name, company description, deal date, deal size, and percent acquired. These fields (except company description) should be included in a precede1nt transaction analysis model:

These transactions were selected based on their relevance to Mersana Therapeutics in terms of industry focus (oncology), therapeutic modalities (targeted therapies, antibody-drug conjugates), and stage of development (primarily clinical-stage assets). The target companies in these deals share similar characteristics with Mersana, making them generally suitable comparables for this analysis.

Refining the list to include more recent transactions and similarly-sized enterprise value firms would improve the comparability and accuracy of the valuation.

Moreover, these transactions involve acquisitions by large, established pharmaceutical companies, reflecting the strong interest and high valuations that promising oncology assets can command in the M&A market. This is relevant for Mersana, as it suggests that the company could potentially attract significant interest from strategic acquirers as its pipeline progresses.

Step #2: Locate the Necessary Deal-Related and Financial Information

Having identified a relevant set of comparable transactions, the next step is to gather the necessary deal-related and financial information for each target company. This data is needed for calculating valuation multiples and determining the implied valuation range for Mersana Therapeutics.

To begin, we need the enterprise value and equity value for each transaction to calculate standard valuation multiples such as EV/Revenue, EV/EBITDA, and the P/E ratio.

Enterprise Value

Enterprise value (EV; aka "transaction value") is a measure of a company's total value, including both equity and debt. It represents the amount an acquirer would pay to purchase the entire company, assuming they also take on its existing net debt obligations.

Here's the enterprise value formula:

Enterprise Value = Equity Value + Total Debt + Preferred Stock + Non-Controlling Interest - Cash and Equivalents

In our case, and in many cases when performing a precedent transaction analysis, enterprise value will be explicitly provided or implied in a database. Therefore, no calculation is necessary for Mersana Therapeutics.

Equity Value

Equity value (aka "equity purchase price" or "offer value") represents the total value of a company's common equity. It's the amount shareholders would receive if all of the company's assets were liquidated and all debts were paid off.

When conducting a precedent transaction analysis, investors must calculate the equity value for each comparable transaction to ensure a consistent basis for comparison. There are two main approaches to deriving equity value, depending on whether the target company is publicly traded or private.

Public Company Approach

For publicly traded companies, the equity value is calculated based on the offer price per share and the number of diluted outstanding shares, as shown in the formula below:

Equity Value = Offer Price Per Share × Diluted Shares Outstanding

This approach takes into account the market price of the company's stock and any premium offered by the acquirer.

The offer price per share is the price offered by the acquirer to purchase the target company's shares. If not provided, it can be calculated as follows:

Offer Price Per Share = Unaffected Share Price + Premium Paid

The unaffected share price is the target company's stock price before any rumors or announcements of the acquisition. The premium paid is the additional amount offered above the unaffected share price to entice shareholders to sell their shares.

Diluted shares outstanding represents the total amount of shares that would be outstanding if all convertible securities, such as options and warrants, were exercised. If not provided, there are two common methods for calculating diluted shares outstanding:

• Treasury Stock Method: Used when the convertible securities are "out of the money" (i.e., the conversion price is higher than the current market price). This method assumes that the proceeds from the exercise of the convertible securities are used to repurchase common shares in the market.
• If-Converted Method: Used when the convertible securities are "in the money" (i.e., the conversion price is lower than the current market price). This method assumes that all convertible securities are converted into common shares.

Purchase Considerations

When calculating equity value, it's important to consider the purchase consideration, which refers to the mix of cash, stock, and/or other securities that the acquirer offers to the target's shareholders. The three primary types of consideration are discussed below.

Purchase Consideration #1: All-Cash Transactions

In an all-cash transaction, the acquirer makes an offer to purchase all or a portion of the target's shares outstanding for cash. The equity value calculation is straightforward:

Equity Value = Cash Offer Price Per Share × Diluted Shares Outstanding

Purchase Consideration #2: Stock-for-Stock Transactions

In a stock-for-stock transaction, the calculation of equity value is based on either a fixed exchange ratio or a floating exchange ratio:

• Fixed Exchange Ratio: Specifies how many shares of the acquirer's stock are exchanged for each share of the target's stock, and remains fixed regardless of price changes. Preferred by the acquirer as it limits their risk of stock price volatility. More common in deals.
• Floating Exchange Ratio: Adjusts the number of acquirer shares exchanged for target shares to ensure a fixed value for target shareholders. Preferred by the target as it guarantees a set value despite stock price changes. Often used when the acquirer is significantly larger.

The exchange ratio formula below applies to both fixed and floating exchange ratios:

Exchange Ratio = Offer Price Per Share / Acquirer's Share Price

For a fixed exchange ratio, this calculation is done once and remains constant throughout the transaction. For a floating exchange ratio, it's recalculated periodically to maintain a fixed value for target shareholders.

Once the exchange ratio is determined, the equity value can be calculated as follows:

Equity Value = (Exchange Ratio × Acquirer's Share Price) × Target's Fully Diluted Shares Outstanding

Purchase Consideration #3: Cash and Stock Transactions

A purchase consideration with a mixture of cash and stock combines elements of both all-cash and stock-for-stock transactions.

For example, consider a $15/share offer for 2M fully diluted shares, funded 60% with stock and 40% with cash. Given this, the cash offer would be $6/share (40% of $15) and the stock offer would be $9/share (60% of $15)

Multiplying the per-share cash offer by the fully diluted shares results in the total cash payment:

Equity Value (Cash Component) = $6/share × 2M shares --> $12M

The $12M represents the total cash consideration that the acquirer will pay to the target company's shareholders.

The stock offer of $9/share would then be inserted into the exchange ratio formula. If we assume the acquirer's share price is $25/share, we can calculate the exchange ratio:

Exchange Ratio = $9/share / $25/share --> 0.36

This means that for each share held of the target company, the shareholder would receive 0.36 shares of the acquirer's stock.

Now, the equity value for the stock component can be calculated as follows:

Equity Value (Stock Component) = 0.36 × $25/share × 2M --> $18M

The $18M represents the total value of the stock consideration offered to the target company's shareholders.

If you add the $12M cash component to the $18M stock component, you get a total equity value of $30M, which is the same as $15/share * 2M. This confirms that the total consideration offered matches the initial $15/share offer price.

For investors conducting a precedent transaction analysis, understanding the breakdown of stock and cash in a deal is important. Cash-heavy deals typically result in higher multiples and premiums, providing immediate and certain value to shareholders. Conversely, stock or mixed offers may result in lower multiples due to the uncertainty of stock value.

Private Company Approach

For private company targets, the equity value calculation is different because there's no public market price to reference. In this case, equity value is derived from the enterprise value, which reflects the overall value of the company including its debt and cash positions.

The formula for calculating equity value in private company transactions is shown below:

Equity Value = Enterprise Value + Cash and Equivalents + Short-Term Investments - Total Debt - Minority Interest

This approach adjusts the enterprise value for the company's cash, debt, and minority interests to arrive at the value of the company's common equity.

In the case of our Mersana Therapeutics example, since we're using PitchBook, we have access to the implied enterprise value and total debt figures, but not equity value. To simplify, and because the offer price per share is not readily available, we'll calculate equity value for each transaction in our model by subtracting the target company's total debt from its implied enterprise value.

This approach is more conservative and addresses the challenge of finding reliable cash and equivalents, short-term investments, and minority interest figures for most of the target companies.

Why Enterprise Value Over Equity Value

Note that it's preferable to use enterprise value multiples when it comes to valuation, as opposed to equity value multiples.

Enterprise value considers a company's debt and is unaffected by its capital structure, whereas equity value is influenced by the company's debt levels. For example, you cannot use the "equity value/EBIT" multiple because equity value is affected by the debt structure, while EBIT is a pre-financing metric and is unaffected by debt.

This is why EBIT and metrics above it on the income statement should be used with enterprise value multiples. Once you include interest expenses and other financing costs, you can use equity value multiples, such as the P/E ratio, which uses net income.

Related: Enterprise Value vs. Equity Value

Revenue, EBITDA, and Net Income

Next, we need to locate the trailing twelve-month (TTM) revenue, EBITDA, and net income for each transaction, which will be used to complete the EV/Revenue, EV/EBITDA, and P/E ratio calculations.

TTM figures provide the most up-to-date financial performance and are not affected by seasonality or one-time events that may occur in a single fiscal quarter or year.

If you don't have access to an M&A database software, then you'd have to pull this information together via the various SEC filings and/or equity research and industry reports discussed prior in this article.

Why You Should Exclude Forward-Looking Figures

In precedent transaction analysis, it's not recommended to use forward-looking figures or estimates, unlike with trading comps. Here are the main reasons on why this is the case:

• It's very difficult to find projections for companies that were acquired years ago at the time of the acquisition.
• It's not always clear if the financial projections include revenue or expense synergies, which can lead to consistency issues.
• The full projections that an acquirer uses to frame its purchase price decision are generally not public and subject to a confidentiality agreement.

Ultimately, this is why multiples for precedent transaction analysis are calculated on the basis of actual TTM financial metrics available at the time of announcement.

Calendarizing Financial Data

Calendarizing financial data involves adjusting a company's financial statements to align with a standard fiscal year, typically the calendar year ending December 31st. This process is crucial in precedent transaction analysis to ensure consistency and comparability across transactions, given that companies' fiscal years may end on different dates.

Calendarizing financial data is recommended when the target company's fiscal year differs from the acquirer's or when comparing transactions announced at different times during the year. However, if the target company's fiscal year already aligns with the calendar year, calendarization is not necessary as the outcome will not change.

Failing to calendarize financial data when needed can lead to inconsistencies in valuation multiples and potentially skew the results of the precedent transaction analysis.

The formula for calendarizing financial data is shown below:

Calendarized Financial Data = [(Overlapping Months Prior FY / 12) × Prior FY Financial Data] + [(Overlapping Months Current FY / 12) × Current FY Financial Data]

where:

• Prior FY: Most recently completed fiscal year before the transaction announcement.
• Current FY: Fiscal year in progress at the time of the transaction announcement.

Related: How to Calendarize Financial Data in Valuation Models

Let's consider an example of a company whose fiscal year ends on March 31st. Here's the information we'll use for our calendarization calculation:

• Prior FY Revenue (Apr 1, 2022 -- Mar 31, 2023) = $200M
• Current FY Revenue (Apr 1, 2023 -- Mar 31, 2024) = $240M

Here's how the number of overlapping months are determined:

• Overlapping Months Prior FY = 3 months (Jan 1, 2023 -- Mar 31, 2023)
• Overlapping Months Current FY = 9 months (Apr 1, 2023 - Dec 31, 2023)

The calendarized revenue would then be calculated as follows:

Calendarized Revenue = [(3 / 12) × $200M] + [(9 / 12) × $240M] --> $50M + $180M --> $230M

The calendarized revenue of $230M represents the adjusted revenue as of the end of the calendar year, aligning the company's fiscal year with the calendar year. This figure provides a more accurate representation of the company's recent financial performance for comparison in precedent transaction analysis.

Step #3: Spread Key Statistics, Ratios, and Transaction Multiples

Once the relevant deal-related and financial information has been collected, investors can "spread" each selected transaction. Spreading a transaction means organizing and analyzing the key data points (i.e., transaction data and financial metrics) in a standardized format, typically using a spreadsheet or database. The relevant multiples for each transaction are then calculated based on this information.

The most commonly used valuation multiples in precedent transaction analysis are EV/Revenue, EV/EBITDA, and P/E ratios. These multiples are considered standard because they provide a comprehensive view of a company's valuation relative to its financial performance.

• EV/Revenue: The EV/Revenue multiple compares a company's enterprise value to its total revenue. It's useful for valuing companies with negative earnings or for comparing companies with different levels of profitability. EV/Revenue is often used for high-growth companies or those in industries with long product development cycles, such as biotech or software.
• EV/EBITDA: The EV/EBITDA multiple is a popular valuation metric that compares a company's enterprise value to its earnings before interest, taxes, depreciation, and amortization. EBITDA is a proxy for cash flow and is less affected by differences in capital structure, taxation, and non-cash items than net income. This multiple is useful for comparing companies with different levels of financial leverage or capital intensity.
• P/E Ratio: The price-to-earnings (P/E) ratio compares a company's equity value (or offer price per share in an acquisition) to its net income (or diluted earnings per share). The P/E ratio is calculated as the offer price per share divided by the target's TTM diluted EPS, or alternatively, as the equity value divided by the target's TTM net income. This multiple is widely used because it directly relates a company's valuation to its bottom-line profitability.

These valuation multiples have been calculated in our precedent transaction analysis model for our Mersana Therapeutics example, providing a comprehensive view of the company's relative valuation.

Sector-Specific Multiples

In addition to these standard multiples, investors may also use specialized multiples tailored to specific industries.

The table below shows various equity value multiples across different sectors (affected by capital structure):

Source: Investment Banking: Valuation, Leveraged Buyouts, and Mergers and Acquisitions (2013) (Equity Value Sector-Specific Multiples)

The table below shows various enterprise value multiples across different sectors (unaffected by capital structure):

Source: Investment Banking: Valuation, Leveraged Buyouts, and Mergers and Acquisitions (2013) (Enterprise Value Sector-Specific Multiples)

Now, let's explore two important aspects of precedent transaction analysis related to spreading: premiums paid and adjusting multiples for synergies.

Premiums Paid

In precedent transaction analysis, premiums paid represent the additional amount per share that the acquirer offers above the target's unaffected share price. Calculating premiums is only applicable when the target company is publicly traded, as it requires historical share price data.

Premiums can provide insight into the level of perceived synergies, strategic value, or competitive bidding for the target company. A higher premium may indicate that the acquirer believes there is significant potential for value creation through the acquisition.

To calculate the premium paid, investors can use the following formula:

% Premium Paid = (Offer Price Per Share / Unaffected Share Price) - 1

For example, if the acquirer offers $180 per share and the target's share price was $120 before the deal announcement, the premium would be calculated as follows:

% Premium Paid = ($180 / $120) - 1 --> 50%

Note that investors can calculate premiums using various timeframes, such as 1 day, 1 week, or 1 month prior to the announcement date. To account for short-term price fluctuations, some analysts also consider 12-month averages or volume-weighted average prices (VWAP) over specific periods.

While premiums offer insights into deal dynamics, they have limited utility in valuation. Unlike multiples or discounted cash flow (DCF) analysis, premiums can't indicate if a company is overvalued, serving mainly to support specific offer prices rather than estimate implied intrinsic value(s).

Due to its limited utility and missing data, we won't include premium analysis in our Mersana Therapeutics example.

Adjusting Multiples for Synergies

Synergies refer to the expected benefits, such as cost savings or revenue enhancements, that result from combining two companies. In precedent transaction analysis, it's highly recommended to adjust valuation multiples for synergies to better understand the price paid by the acquirer.

Different types of synergies (as discussed prior) that can impact the valuation multiples are summarized below:

• Strategic vs. Financial Buyers: Strategic buyers often have a greater ability to realize synergies due to industry expertise and operational overlap, leading to higher valuation multiples compared to financial buyers.
• Motivations Behind the Transaction: Transactions driven by specific strategic objectives, such as acquiring unique technologies or expanding into new markets, may command higher multiples.
• Sale Process and Nature of the Deal: Competitive auction processes or hostile takeovers can drive up valuation multiples, while negotiated deals or mergers of equals may result in lower multiples.
• Purchase Consideration: The form of consideration (cash, stock, or a combination) can impact the valuation multiples, with all-cash deals often resulting in higher multiples due to the immediate liquidity provided to the target's shareholders.
• Domestic vs. Cross-Border Transactions: Cross-border deals may involve additional complexities, such as regulatory hurdles or cultural differences, which can affect the valuation multiples.

To illustrate the impact of synergies on valuation multiples, consider an example where the enterprise value is $1,500M, the target's TTM EBITDA is $120M, and the expected annual run-rate cost synergies are $30M:

EV / TTM EBITDA = $1,500M / $120M --> 12.5x

EV / (TTM EBITDA + Synergies) = $1,500M / ($120M + $30M) --> 10.0x

The decrease in the EV/EBITDA multiple from 12.5x to 10.0x after adjusting for synergies indicates that the deal becomes relatively cheaper when considering the expected cost savings. This lower multiple reflects the acquirer's anticipation of increased profitability post-merger, making the initial purchase price more attractive when factoring in these synergies.

For simplicity, we won't include synergy adjustments in our Mersana Therapeutics example.

Step #4: Benchmark the Comparable Acquisitions

After calculating the key statistics, ratios, and transaction multiples for each comparable acquisition, the next step is to benchmark these metrics to identify trends, outliers, and valuation ranges. This process involves comparing the multiples across transactions and analyzing the factors that may have influenced the valuation in each case, and is very similar to trading comps.

To begin benchmarking, investors should create a model displaying the transaction multiples for each comparable acquisition. This model should include EV/Revenue, EV/EBITDA, and P/E ratios/multiples, as well as any relevant industry-specific multiples. Optionally, the model can include the premiums paid over various timeframes, such as 1 day, 1 week, or 1 month before the announcement date.

Once the model is created, investors should analyze the data to identify patterns and trends. For example:

• Look for clustering of multiples within a certain range, which may indicate a typical valuation level for the industry.
• Identify outliers or transactions with significantly higher or lower multiples and investigate the reasons behind these differences (e.g., unique deal terms, strategic rationale, or company-specific factors). Creating a conditional format to highlight lower multiples in green (indicating cheaper relative to other comps) and higher multiples in red (indicating more expensive relative to other comps) is helpful here.
• Compare the premiums paid across transactions and consider the factors that may have influenced the acquirer's willingness to pay a higher or lower premium (e.g., competitive bidding process, strategic fit, or market conditions).

In addition to comparing multiples and premiums, investors should also consider qualitative factors that may have impacted the valuation in each transaction. These factors could include the target company's stage of development, the strength of its product pipeline, the addressable market opportunity, and the expected synergies or strategic benefits for the acquirer.

Here's what our Mersana Therapeutics benchmarked model looks like:

From this analysis, we can observe that Mersana Therapeutics is trading relatively cheaply on an EV/Revenue and P/E ratio basis compared to its benchmarked peers. Additionally, because most of our comparable M&A deals operate with negative EBITDA and net income, most of the EV/EBITDA and P/E ratios are negative as well. This suggests that we should imply the valuation range for Mersana Therapeutics based on its EV/Revenue multiple.

This analysis also helps evaluate whether any of the 10 benchmarked companies are not comparable to Mersana Therapeutics. In our case, with many of the precedent transactions selling for significantly higher enterprise and equity values, and in some cases significantly higher trading multiples, it suggests that the selected transactions could be refined further.

Calculate Summary Statistics

After analyzing the comparable acquisitions individually, investors should calculate the summary statistics to identify trends and establish a range of valuation multiples. This range of valuation multiples will be used in Step #5 to imply Mersana Therapeutics' valuation.

These summary statistics include the maximum, 75th percentile, mean (aka average), median, 25th percentile, and minimum, and can be included in the model as follows:

Typically, investors use the mean or median multiples to calculate the implied valuation, as these measures are less affected by outliers compared to the minimum or maximum values. However, the choice of multiples may depend on the specific characteristics of the comparable transactions and the target company.

If we focus on just the EV/Revenue multiples for our benchmarked comparable deals, we can observe that the range varies widely from 7.6x to 538.7x, with the mean and median at 114.9x and 28.7x, respectively. This wide range indicates significant variability in the valuation of comparable companies, suggesting the need for careful selection of appropriate multiples.

Step #5: Imply Valuation

In the final step of the precedent transaction analysis, we apply the valuation multiples derived from the comparable acquisitions to Mersana Therapeutics' financial metrics to estimate its implied valuation range. Again, this process is very similar to trading comps.

Implied Enterprise Value

To begin, calculate the implied enterprise value range by multiplying Mersana Therapeutic's TTM revenue and EBITDA by the corresponding multiples (across all the different summary statistics):

Implied Enterprise Value (Revenue) [MRSN; TTM] = 7.6x to 538.7x × $38.30M (TTM Revenues) --> $293M to $20,630M

Implied Enterprise Value (EBITDA) [MRSN; TTM] = -128.9x to 176.5x × -$139.22M (TTM EBITDA) --> $17,949M to -$24,575M

The implied enterprise value range of $293M to $20,630M based on revenue multiples indicates a wide range of potential valuations for Mersana Therapeutics. As previously suggested, we'll disregard the implied enterprise value range for EBITDA since most of the comparables, including Mersana Therapeutics, have negative EBITDA figures.

Implied Equity Value

Next, bridge from the implied enterprise value to implied equity value to determine the value attributable to equity shareholders, using the formula shown below:

Equity Value = Enterprise Value + Cash and Equivalents + Short-Term Investments - Total Debt - Minority Interest

We need to collect TTM financial data for Mersana Therapeutic's cash and equivalents, short-term investments, total debt, and minority interest, which can be found or calculated from the company's balance sheet and/or 10-K annual reports.

Once these financials have been collected, we can calculate the implied equity value ranges for Mersana Therapeutics as follows:

Implied Equity Value (Revenue) [MRSN; TTM] = $293M to $20,630M + [$183.15M (TTM Cash and Equivalents + Short-Term Investments) - $28.85M (TTM Total Debt + Minority Interest)] --> $447M to $20,784M

Implied Equity Value (EBITDA) [MRSN; TTM] = $17,949M to -$24,575M + [$183.15M (TTM Cash and Equivalents + Short-Term Investments) - $28.85M (TTM Total Debt + Minority Interest)] --> $18,104M to -$24,420M

The implied equity value range of $447M to $20,784M represents the potential value of Mersana Therapeutics' equity based on the precedent transactions. Again, we'll ignore the implied equity value for EBITDA in this example, but the calculation is shown above for demonstration purposes.

To derive the implied equity value for net income, the process is different. We need to find Mersana Therapeutics' TTM diluted shares and TTM diluted EPS. These figures can be found in the company's income statement or earnings release. Diluted figures are preferred over basic because they account for all potential shares that could be issued, providing a more conservative estimate. Diluted shares are also necessary in the final step to calculate the per-share intrinsic/fair value range.

The implied equity value for net income can be calculated using the formula:

Implied Equity Value (Net Income) = Implied P/E Ratio × (Diluted EPS × Diluted Shares Outstanding)

This formula works differently from the revenue and EBITDA calculations because it directly uses per-share metrics. By multiplying the diluted EPS by the number of diluted shares, we get the total net income. Applying the implied P/E ratio to this figure scales the company's earnings to match valuation levels seen in comparable transactions, resulting in an implied equity value.

This method is more direct for net income-based valuations, as it doesn't require adjustments for debt and cash like the enterprise value-based calculations for revenue and EBITDA.

Here's the completed equity value net income calculation for Mersana Therapeutics:

Implied Equity Value (Net Income) [MRSN; TTM] = -0.4x to ~0.0x × [-$1.48 (TTM Diluted EPS) × 121.42M (TTM Diluted Shares)] --> $70M to -$1M

The implied equity value range of $70M to -$1M based on net income multiples is not meaningful for valuation purposes due to Mersana Therapeutics' negative earnings. Similar to the EBITDA-based valuation in our case, we'll ignore this range in our analysis.

Implied Share Prices

Finally, to calculate the implied share price range, divide the implied equity values for revenues, EBITDA, and net income by Mersana Therapeutics' TTM diluted shares outstanding:

Implied Share Price (Revenue) [MRSN; TTM] = $447M to $20,784M / 121.42M (TTM Diluted Shares) --> $3.68 to $171.17

Implied Share Price (EBITDA) [MRSN; TTM] = $18,104M to -$24,420M / 121.42M (TTM Diluted Shares) --> $149.09 to -$201.11

Implied Share Price (Net Income) [MRSN; TTM] = $70M to -$1M / 121.42M (TTM Diluted Shares) --> $0.58 to $0.01

This process, repeated for each relevant valuation multiple, results in a range of implied valuations for Mersana Therapeutics based on the precedent transaction analysis.

The final implied share price range of $3.68 to $171.17 based on revenue multiples suggests a wide range of potential valuations. Compared to Mersana Therapeutics' current stock price of ~$2.04, this range indicates that the stock may be undervalued according to the precedent transaction analysis, as even the lower end of the range is higher than the current trading price.

Football Field Valuation Chart

To present the results of the precedent transaction analysis, investors often use a football field chart. This visual representation displays the implied valuation ranges derived from different multiples (e.g., EV/Revenue, EV/EBITDA, and P/E) as horizontal bars on a chart, with the target company's current valuation or trading price shown as a vertical line.

Here's a simple football field chart for our Mersana Therapeutic example, with its 52-week high/low prices and EV/Revenue multiple range plotted:

As you can see, the football field chart helps to summarize the key findings of the analysis and provides a clear comparison of the implied valuation ranges to the target company's current valuation.

Advantages of Precedent Transaction Analysis

Precedent transaction analysis offers a useful approach for estimating a company's value based on prices paid in recent, comparable transactions. This section provides an overview of the key advantages associated with this valuation method, as discussed below:

• Grounded in Reality: Precedent transaction analysis is based on actual prices paid for real-life deals, reflecting the market's assessment of value at a specific point in time. Unlike methods relying on traded multiples or future projections, precedent transactions provide a concrete basis for assessing a company's worth.
• Offers Perspective on Takeover Potential: By analyzing recent transactions in a given industry, investors can gauge the likelihood of takeover activity and potential acquisition premiums for similar companies.
• Reveals Market Trends: This approach can uncover information about market trends, such as industry consolidation or foreign investment. If transactions in an industry show increasing valuation multiples over time, it may indicate growing investor interest. This information helps investors understand the competitive landscape.
• Reflects Current Conditions: Similarly, recent transactions provide insight into the current market, considering prevailing economic conditions and industry trends. This ensures the valuation aligns with market realities.
• Incorporates Synergies and Strategic Value: Transaction prices often include premiums reflecting potential synergies or strategic value. This can provide insights into a company's full potential value, which may not be fully reflected in its current stock price.

In conclusion, precedent transaction analysis offers several advantages as a valuation method. Primarily, it provides a realistic and objective basis for assessing a company's worth. The methodology is also theoretically straightforward, focusing on key valuation multiples, making the process more accessible to investors.

Limitations of Precedent Transaction Analysis

While precedent transaction analysis can be useful for estimating a company's value based on comparable historical transactions, it is important to recognize its limitations. This section provides an overview of the shortcomings associated with this valuation method, as described below:

• Limited Comparability: Finding truly comparable transactions is challenging, as no two companies or deals are identical. Differences in business models, growth rates, profitability, market position, and other factors can significantly impact valuation. For instance, comparing a high-growth technology firm to a mature company in the same industry may yield misleading results due to their distinct financial profiles and growth prospects.
• Deal-Specific Factors: The price paid in a transaction may be influenced by factors specific to that deal, such as expected synergies, competitive bidding, or the negotiating power of the parties involved. These factors may not apply to the target company being valued. For instance, if a strategic buyer paid a premium for a target company due to anticipated cost savings from combining operations, that premium may not be relevant when valuing a similar company without such synergistic opportunities.
• Limited Information Availability: Detailed financial information for private transactions may not be publicly available, reducing the pool of comparable transactions. This is particularly true for smaller, private deals where disclosure requirements are less stringent. Consequently, the analysis may rely on a smaller sample size or incomplete information, potentially affecting the accuracy of the valuation.
• Timing and Market Conditions: The relevance of older transactions diminishes as market conditions, industry trends, and company-specific factors change over time. Transactions that occurred during a recession or before a significant industry disruption may not be representative of current market dynamics.
• Control Premium and Minority Discounts: Transaction prices often include a control premium, reflecting the value of gaining control over the target company. This premium may not apply when valuing a minority stake or a company not actively considering a sale. Conversely, minority discounts may be applied when valuing non-controlling interests, as they lack the ability to influence key decisions. Failing to properly account for these factors can lead to over- or undervaluation.
• Unique Transaction Circumstances: Each transaction has its own set of unique circumstances that may not be fully captured by valuation multiples. For example, the existence of commercial agreements, governance issues, or specific tax considerations (e.g., a Section 338(h)(10) election) can impact the transaction price but may not be relevant to the target company's valuation.
• Wide Range of Valuation Outcomes: Due to the inherent variability in transaction multiples and the unique characteristics of each deal, the values obtained from precedent transaction analysis can vary widely. This can limit the usefulness of summary metrics, such as the mean or median multiple, in establishing a definitive valuation for the target company.
• Acquirer's Valuation Basis: The multiple paid by the acquirer may be based on expectations of future performance rather than the target company's current or historical financial metrics. This can lead to discrepancies when applying these multiples to the target company's actual performance, particularly if the acquirer's expectations were overly optimistic or if the target company's growth trajectory differs significantly from the acquired company's.

In conclusion, while precedent transaction analysis can provide valuable insights into a company's potential value, it's crucial to recognize its limitations. The lack of truly comparable transactions, deal-specific factors, limited information availability, and the impact of market conditions can all affect the accuracy and reliability of the analysis. Additionally, the wide range of valuation outcomes and the acquirer's valuation basis can further complicate the interpretation of results.

To mitigate these limitations, it's advisable to use precedent transaction analysis alongside other valuation methods and carefully consider transaction comparability, data quality, and the target company's unique characteristics when drawing conclusions.

The Bottom Line

Precedent transaction analysis is a relative valuation method that estimates a company's worth by examining the prices paid for similar companies in recent mergers and acquisitions (M&A). This approach provides insights into the valuation levels that acquirers are willing to pay for companies with comparable characteristics, helping to determine a fair price range for a potential acquisition target or initial public offering (IPO).

Identifying relevant precedent transactions requires considering factors such as industry, business model, financials, size, and growth stage. The more similar the target companies are to the one being valued, the more accurate and meaningful the valuation insights will be. Understanding the specific transaction dynamics, such as the presence of synergies or the nature of the buyers (strategic vs. financial), can also help refine the analysis and adjust for any unique circumstances.

To find relevant precedent transaction information, investors can utilize various sources, including financial databases, company filings, and equity/industry research reports. The key information needed for the analysis includes the transaction details (e.g., purchase price, announcement date), target company financials (e.g., revenue, EBITDA, net income), and any relevant deal-related data (e.g., synergies, strategic rationale).

While precedent transaction analysis offers valuable insights into M&A valuation dynamics, it has some limitations. The process can be time-intensive, requiring significant research and data gathering. Additionally, accessing complete and accurate data for private transactions can be challenging, limiting the scope of the analysis. The quantity of truly comparable transactions may also be limited, particularly for niche industries or unique business models. Moreover, the valuation multiples derived from precedent transactions may not always reflect the current market conditions or company-specific factors.

Despite these limitations, precedent transaction analysis remains a useful model for estimating a company's value in the context of M&A, given that it's grounded in reality with actual transaction prices, providing a tangible basis for stock valuation.